Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC)

被引：23

作者：

Moreno, Maria ^{[1
,2
]}

Mol, Berber M. ^{[1
]}

von Mensdorff-Pouilly, Silvia ^{[2
]}

Verheijen, Rene H. M. ^{[3
]}

von Blomberg, B. Mary E. ^{[1
]}

van den Eertwegh, Alfons J. M. ^{[4
]}

Scheper, Rik J. ^{[1
]}

Bontkes, Hetty J. ^{[1
]}

机构：

[1] Vrije Univ Amsterdam Med Ctr, Dept Pathol, NL-1081 HV Amsterdam, Netherlands

[2] Vrije Univ Amsterdam Med Ctr, Dept Obstet & Gynaecol, NL-1081 HV Amsterdam, Netherlands

[3] Univ Med Ctr Utrecht, Dept Woman & Baby, Div Surg & Oncol Gynaecol, Utrecht, Netherlands

[4] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands

来源：

CANCER LETTERS | 2008年 / 272卷 / 01期

关键词：

Human; Invariant NKT cells; Toll-like receptors; NK cells; ADCC;

D O I：

10.1016/j.canlet.2008.06.028

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

huHMFG-1 (AS1402) is a humanised IgG1 against MUC1, which exerts tumour cell killing through antibody-dependent cellular cytotoxicity (ADCC) mediated by natural killer (NK) cells. Here, we explored the capacity of invariant NKT (iNKT) cells, which are known to activate NK cells, and toll-like receptor (TLR) ligands which activate both iNKT and NK cells, to enhance huHMFG-1-ADCC. Addition of iNKT cells, as well as TLR2/6, 7, 8 and 9 agonists to PBMC improved the efficacy of huHMFG-1. These results suggest that transfer of ex vivo expanded iNKT cells or TLR agonist treatment may improve the efficacy of NK cell-mediated antibody-based tumour immunotherapies. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：70 / 76

页数：7

共 25 条

[1] Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein
Fujii, S
Shimizu, K
Smith, C
Bonifaz, L
Steinman, RM
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (02) : 267 - 279
[2] NKT cells: facts, functions and fallacies
Godfrey, DI
Hammond, KJL
Poulton, LD
Smyth, MJ
Baxter, AG
[J]. IMMUNOLOGY TODAY, 2000, 21 (11): : 573 - 583
[3] Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists
Gorski, Kevin S.
Waller, Emily L.
Bjornton-Severson, Jacqueline
Hanten, John A.
Riter, Christie L.
Kieper, William C.
Gorden, Keith B.
Miller, Jeffrey S.
Vasilakos, John P.
Tomai, Mark A.
Alkan, Sefik S.
[J]. INTERNATIONAL IMMUNOLOGY, 2006, 18 (07) : 1115 - 1126
[4] TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-γ production
Hart, OM
Athie-Morales, V
O'Connor, GM
Gardiner, CM
[J]. JOURNAL OF IMMUNOLOGY, 2005, 175 (03) : 1636 - 1642
[5] HO SB, 1993, CANCER RES, V53, P641
[6] Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides
Hornung, V
Rothenfusser, S
Britsch, S
Krug, A
Jahrsdörfer, B
Giese, T
Endres, S
Hartmann, G
[J]. JOURNAL OF IMMUNOLOGY, 2002, 168 (09) : 4531 - 4537
[7] What makes MUC1 a tumor antigen?
Karsten, U
von Mensdorff-Pouilly, S
Goletz, S
[J]. TUMOR BIOLOGY, 2005, 26 (04) : 217 - 220
[8] Toward an understanding of NKT cell biology: Progress and paradoxes
Kronenberg, M
[J]. ANNUAL REVIEW OF IMMUNOLOGY, 2005, 23 : 877 - 900
[9] The direct effects of Toll-like receptor ligands on human NK cell cytokine production and cytotoxicity
Lauzon, Nicole M.
Mian, Firoz
MacKenzie, Randy
Ashkar, Ali A.
[J]. CELLULAR IMMUNOLOGY, 2006, 241 (02) : 102 - 112
[10] Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non-hodgkin's lymphoma
Leonard, John R.
Link, Brian K.
Emmanouilides, Christos
Gregory, Stephanie A.
Weisdorf, Daniel
Andrey, Jeffrey
Hainsworth, John
Sparano, Joseph A.
Tsai, Donald E.
Horning, Sandra
Krieg, Arthur M.
Weiner, George J.
[J]. CLINICAL CANCER RESEARCH, 2007, 13 (20) : 6168 - 6174

← 1 2 3 →